| Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab L Brill, A Rechtman, O Zveik, N Haham, E Oiknine-Djian, DG Wolf, N Levin, ... JAMA neurology 78 (12), 1510-1514, 2021 | 157 | 2021 |
| Severe acute respiratory syndrome coronavirus 2 third vaccine immune response in multiple sclerosis patients treated with ocrelizumab L Brill, C Raposo, A Rechtman, O Zveik, N Levin, E Oiknine‐Djian, ... Annals of neurology 91 (6), 796-800, 2022 | 29* | 2022 |
| Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells O Zveik, N Fainstein, A Rechtman, N Haham, T Ganz, I Lavon, L Brill, ... Glia 70 (6), 1191-1209, 2022 | 23 | 2022 |
| Volumetric brain loss correlates with a relapsing MOGAD disease course A Rechtman, L Brill, O Zveik, B Uliel, N Haham, AS Bick, N Levin, ... Frontiers in Neurology 13, 867190, 2022 | 20 | 2022 |
| Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis L Brill, A Rechtman, O Zveik, N Haham, N Levin, A Shifrin, A Rozenberg, ... Multiple Sclerosis and Related Disorders 57, 103343, 2022 | 20 | 2022 |
| IL-6 as a marker for NMOSD disease activity A Haramati, A Rechtman, O Zveik, N Haham, L Brill, A Vaknin-Dembinsky Journal of Neuroimmunology 370, 577925, 2022 | 11 | 2022 |
| Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine L Brill, A Rechtman, A Shifrin, A Rozenberg, S Afanasiev, O Zveik, ... Multiple Sclerosis and Related Disorders 63, 103863, 2022 | 7 | 2022 |
| Oligodendrocyte progenitor cells differentiation induction with MAPK/ERK inhibitor fails to support repair processes in the chronically demyelinated CNS T Ganz, O Zveik, N Fainstein, M Lachish, A Rechtman, L Sofer, L Brill, ... Glia 71 (12), 2815-2831, 2023 | 5 | 2023 |
| Sera of neuromyelitis optica patients increase BID-mediated apoptosis in astrocytes O Zveik, A Rechtman, N Haham, I Adini, T Canello, I Lavon, L Brill, ... International Journal of Molecular Sciences 23 (13), 7117, 2022 | 4 | 2022 |
| Anti‐and pro‐inflammatory milieu differentially regulate differentiation and immune functions of oligodendrocyte progenitor cells O Zveik, A Rechtman, L Brill, A Vaknin‐Dembinsky Immunology 171 (4), 618-633, 2024 | 3 | 2024 |
| Thyroid hormone dysfunction in MOGAD and other demyelinating diseases A Rechtman, O Zveik, N Haham, T Freidman-Korn, A Vaknin-Dembinsky Journal of the Neurological Sciences 457, 122866, 2024 | 1 | 2024 |
| Dual positivity for anti-mog and oligoclonal bands: Unveiling unique clinical profiles and implications E Ganelin-Cohen, S Shelly, Y Schiller, A Vaknin-Dembinsky, M Shachor, ... Multiple Sclerosis and Related Disorders 79, 105034, 2023 | 1 | 2023 |
| The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells O Zveik, A Rechtman, T Ganz, A Vaknin-Dembinsky Molecular Neurodegeneration 19 (1), 53, 2024 | | 2024 |
| A protective effect of lower MHC-II expression in MOGAD A Rechtman, O Zveik, N Haham, L Brill, A Vaknin-Dembinsky Journal of Neuroimmunology 391, 578351, 2024 | | 2024 |
| Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings A Rechtman, T Freidman-Korn, O Zveik, L Shweiki, G Hoichman, ... Journal of Neurology, 1-7, 2024 | | 2024 |
| Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD N Haham, O Zveik, A Rechtman, L Brill, A Vaknin-Dembinsky Journal of Neuroimmunology 388, 578289, 2024 | | 2024 |
| Myelin oligodendrocyte glycoprotein antibody‐associated disease presenting with dystonia O Zveik, T Benoliel Berman, T Keadan, K Barhum, A Rechtman, ... Neurology and Clinical Neuroscience 12 (1), 65-67, 2024 | | 2024 |
| Brain MRI activity during the year before pregnancy can predict long-term clinical worsening in patients with Multiple Sclerosis S Kahila, O Zveik, N Levin, L Brill, A Rechtman, N Haham, T Imbar, ... Neurological Sciences 44 (11), 3989-3996, 2023 | | 2023 |
| Short and long-term serology response of MS patients treated with natalizumab following two doses of mRNA COVID-19 vaccine (Pfizer) L Brill, A Rechtman, A Shifrin, A Rozenberg, S Afanasiev, O Zveik, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 871-871, 2022 | | 2022 |
| Using circulatory biomarkers to predict disease progression in multiple sclerosis (MS) N Haham, L Brill, N Rappoport, O Zveik, A Rechtman, ... Multiple Sclerosis Journal 27 (2_SUPPL), 531-531, 2021 | | 2021 |
Omri ZveikMD-PhD student, Hebrew University of Jerusalem在 mail.huji.ac.il 的电子邮件经过验证
